NextCure, Inc. Profile Avatar - Palmy Investing

NextCure, Inc.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is i…

Biotechnology
US, Beltsville [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of NXTC's Analysis
CIK: 1661059 CUSIP: 65343E108 ISIN: US65343E1082 LEI: - UEI: -
Secondary Listings
NXTC has no secondary listings inside our databases.